Rocket Pharmaceuticals Receives FDA RMAT Designation

Rocket Pharmaceuticals ( (RCKT) ) has provided an announcement.

On July 17, 2025, Rocket Pharmaceuticals announced that the FDA granted RMAT designation to its investigational gene therapy, RP-A601, for PKP2-arrhythmogenic cardiomyopathy (ACM). This designation, based on positive Phase 1 trial data, offers expedited FDA review and guidance, marking a significant advancement for the company and patients with this life-threatening condition.

The most recent analyst rating on (RCKT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.

Spark’s Take on RCKT Stock

According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.

Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.

To see Spark’s full report on RCKT stock, click here.

More about Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on developing genetic therapies for rare disorders. The company employs a multi-platform approach to create gene therapies aimed at treating complex and rare diseases, with a portfolio that includes programs for cardiovascular and hematologic conditions.

Average Trading Volume: 4,897,948

Technical Sentiment Signal: Sell

Current Market Cap: $302.7M

For an in-depth examination of RCKT stock, go to TipRanks’ Overview page.